Acūtis

Acutis Reveal[™] PIT pharyngeal infection test

Acutis Reveal^M PIT is a new FDA-cleared molecular test that quickly identifies the Group A β -hemolytic *Streptococcus* pyogenes pathogen responsible for **Strep A** disease.

This single-step process eliminates the need for a culture backup, a procedure that can take 2 or even 3 days to confirm a diagnosis. This delay can have both tangible and intangible effects. On the one hand, it adds to off ice backlogs, and on the other, contributes to an adult patient's anxiety, or to that felt by a patient's parent.

The FDA-cleared molecular detection test that simplifies the clinical scenario

	Acutis Reveal [™] PIT	Culture	In-office test (rapid antigen strep test)
Sensitivity	97.5%	89.9% - 99.6%	64.6%
Specificity	97.8%	98.2% - 99.5%	96.79%
Negative predictive value	99. 1%	100%	92.82%
Confirmation requirements	Νο	No	Culture confirmation is required
Number of steps	1	1	2
Turnaround time	Within 24 hours of sample receipt	2-3 days	Same day

The FDA-approved test detects the major pharyngeal pathogen responsible for Strep A

Bacterial targets

Streptococcus pyogenes

A fast, one-step FDA-cleared procedure that requires only a simple throat swab and transport media ----

Rapid confirmation, within 24 hours from the time a sample is received



A higher degree of certainty, which helps determine whether or not a course of antibiotics is necessary



Why choose Acutis Reveal[™]?

A common complaint that can conceal complexity

Strep A is shorthand for *Streptococcus pyogenes*. Unlike most sore throats, which are caused by a viral infection, Strep A is a bacterial pathogen. Once diagnosed properly and in a timely fashion, it is easily treated. But ignored, even minor infections can flare into serious illnesses such as Scarlet Fever, Rheumatic Fever, and other troubling ailments.

This condition is also highly contagious and can be spread by people who show no symptoms of the illness. Strep A can be spread by coughs and sneezes, by touching contaminated surfaces, even by drinking from the glass or eating from a plate used by an infected person.

Strep A often occurs in clusters, frequently among school-age children, which could explain how your patient's child contracted his or her illness. We emphasize children here because while approximately 11 million people are diagnosed with pharyngeal infections each year, up to 30% of those who contract Strep A are children. Adults account for as many as 15% of the diagnoses. What's more, this respiratory disease is also identified with healthcare-associated postpartum and post-surgical infections.

Molecular detection accelerates the process while eliminating doubts

Acutis Reveal™ PIT (Strep A) is an FDA-cleared molecular detection technology that is appropriate for a range of healthcare facilities from pediatric and family practices to infectious disease specialists and urgent care facilities. It is a highly calibrated technology conceived to diagnosis Group A β-hemolytic *Streptococcus pyogenes*, quickly and with superior accuracy.

Among the most important benefits of accurate results is how they discourage the unnecessary or over-prescribing of antibiotics. Acutis Reveal[™] PIT offers an additional layer of protection from these kinds of errors.

Accurate data, delivered within 24 hours of the time the sample arrives at our lab, enables physicians and other healthcare providers to introduce a new level of efficiency into the office, allowing physicians and their practices to focus on more critical complaints.

> To learn more ↓ 844-522-8847 service@acutis.com acutis.com

400 Karin Lane, Hicksville, NY 11801 68 Culver Road, Suite 150B, Monmouth Junction, NJ 08852 Fax 631-532-1680